betaSENSE
betaSENSE is a pioneering company dedicated to revolutionizing early diagnosis of neurodegenerative diseases such as Alzheimer's, Parkinson, and ALS through innovative platform technology. Their mission is to enable early detection, facilitate timely treatment, and support self-determination in aging, by providing simple, accurate, and non-invasive protein-based diagnostic tests. Originating from the Ruhr-Universität Bochum, betaSENSE combines scientific excellence with practical application to improve patient outcomes and advance research in proteomics.
Industries
Nr. of Employees
small (1-50)
betaSENSE
Patents
Attenuated total reflectance-based biosensor for conformation and secondary structure analysis
US-12031907-B2
View DetailsAttenuated total reflectance-based biosensor for conformation and secondary structure analysis
US-11073470-B2
View Details
Attenuated total reflectance-based biosensor for conformation and secondary structure analysis
US-12031907-B2
View DetailsAttenuated total reflectance-based biosensor for conformation and secondary structure analysis
US-11073470-B2
View DetailsProducts
Protein structural biomarker diagnostic test (in development)
A laboratory diagnostic test that detects misfolding of disease-associated proteins in body fluids using antibody capture followed by infrared structural analysis to estimate future risk of neurodegenerative disease.
Protein structural biomarker diagnostic test (in development)
A laboratory diagnostic test that detects misfolding of disease-associated proteins in body fluids using antibody capture followed by infrared structural analysis to estimate future risk of neurodegenerative disease.
Services
Laboratory measurement of structural protein biomarkers using an immuno-infrared spectroscopy platform to support drug-discovery research and pharmacodynamic readouts.
Provision of in-house and reference-laboratory capabilities for analytical validation and study-associated diagnostic validation.
Biomarker-based screening to identify and stratify participants for clinical trials and refine inclusion criteria based on structural biomarker risk.
Provision of a fluid-based diagnostic test to assess individual risk of neurodegenerative disease from a small-volume sample; currently undergoing regulatory approval processes.
Laboratory measurement of structural protein biomarkers using an immuno-infrared spectroscopy platform to support drug-discovery research and pharmacodynamic readouts.
Provision of in-house and reference-laboratory capabilities for analytical validation and study-associated diagnostic validation.
Biomarker-based screening to identify and stratify participants for clinical trials and refine inclusion criteria based on structural biomarker risk.
Provision of a fluid-based diagnostic test to assess individual risk of neurodegenerative disease from a small-volume sample; currently undergoing regulatory approval processes.
Expertise Areas
- Proteindiagnostics and structural biomarker analysis
- Early detection diagnostics for neurodegenerative diseases
- Assay development and customization for protein biomarkers
- Laboratory validation and reference-lab operations
Key Technologies
- Immuno-infrared spectroscopy
- Antibody-based biomarker capture/enrichment
- Fluid-based structural biomarker analysis (blood, CSF)
- Assay platform customization
News & Updates
Visit by NRW Minister Mona Neubaur to the startup, highlighting its role in medical innovation.
Recognition of betaSENSE's innovative approach in neurodiagnostics.
Research article on measuring misfolded alpha-synuclein using the iRS platform.
Study on early biomarkers for Alzheimer’s disease.
Research on structure-based biomarker for ALS.
Award received for innovative neurodiagnostic technology.
Visit by NRW Minister Mona Neubaur to the startup, highlighting its role in medical innovation.
Recognition of betaSENSE's innovative approach in neurodiagnostics.
Research article on measuring misfolded alpha-synuclein using the iRS platform.
Study on early biomarkers for Alzheimer’s disease.
Research on structure-based biomarker for ALS.
Award received for innovative neurodiagnostic technology.